Patent approved in Europe
SpectraCure's patent application for a new technology, to improve the company's IDOSE® technology, has been approved by the European Patent Office, EPO. The IDOSE® technology is central to SpectraCure's method of treating prostate cancer with photodynamic tumor therapy (PDT). In short, IDOSE® technology means that the prostate tissue is monitored during treatment with a series of different measurements to ensure that the correct dose is given, so that the tumour is eliminated, without damaging healthy surrounding tissue. The new patent protects a method for detecting and compensating for